founded by Yoshi Koide in 1997. The main objectives of Probiohealth are to manufacture and distribute scientifically validated probiotic products in combination with natural bioactive ingredients. After years of rigorous screening procedures, the isolation and identification of Lactobacillus casei strain KE-99 has formed the commercial basis for Probiohealth's first product development. Following a successful validation of the probiotic potential of this super strain at independent laboratories and controlled human clinical trials, in the year 2000, Probiohealth has successfully launched this probiotic into the market as KE-99 LACTO. In 2002, the R&D laboratory of Probiohealth has further developed an innovative oil-based preservative/prebiotic system using a nitrogen-purged instant bonding (NPIB) technique for functional delivery of probiotic products intended for human and animal health applications. In 2002, Probiohealth has introduced these novel lines of oil-based KE-99 products (with NPIB encapsulation technique) into the market. This new product line is gaining an instant popularity in North America, Japan and other Asian markets. Probiohealth fully recognizes that a strong technical teamwork is the fundamental backbone for its probiotic commercialization. Accordingly, Probiohealth is supported by a cutting-edge R&D laboratory group for new product development; several leading scientific investigators from academia as well as clinical institutions around the world for scientific advisory and validations; fermentation, manufacturing and packaging facilities with standardized GMPs, critical controls and certifications; and finally a stringent Q/A and Q/C program with a Multi Point Product Variability Check System. Probiohealth is continuously searching for the identification and isolation of new super strains with measurable health benefits and actively involved in the development of novel delivery systems for probiotic supplements for enhancing human and animal health.